We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
22 May 2021 - 26 May 2021
Virtual Venue
25 May 2021 - 28 May 2021

TFP Inhibitor Levels Elevated in Bleeding Tendency Patients

By LabMedica International staff writers
Posted on 11 Feb 2021
Print article
Image: The Technothrombin TGA is a thrombin generation assay (TGA) based on monitoring the formation of thrombin by means of a fluorogenic substrate upon activation of the coagulation cascade by tissue factor (Photo courtesy of Technoclone).
Image: The Technothrombin TGA is a thrombin generation assay (TGA) based on monitoring the formation of thrombin by means of a fluorogenic substrate upon activation of the coagulation cascade by tissue factor (Photo courtesy of Technoclone).
Mild to moderate bleeding disorders (MBDs) are characterized by symptoms such as epistaxis, easy bruising, or menorrhagia, but bleeding can also be severe under certain circumstances such as hemorrhage after surgery or birth.

Tissue factor (TF) pathway inhibitor (TFPI) is a pivotal anticoagulant player in hemostasis, regulating TF-induced coagulation. Among the two major isoforms, free TFPIα, primarily produced in endothelial cells, is the only anticoagulant isoform found in blood circulation.

Hematologists at the Medical University Vienna (Vienna, Austria) investigated free TFPIα in a well-characterized cohort of 620 patients with mild to moderate bleeding tendencies and its association to genetic alterations in the F5 gene. One hundred age- and sex-matched healthy controls without a clinical bleeding tendency were recruited by trained health care personnel for comparison.

Quantification of free TFPIα levels was performed in plasma samples using a standardized enzyme-linked immunosorbent assay, the Asserachrom Free TFPI-ELISA, (Stago, Asnières sur Seine, France). Thrombin generation was assessed with the commercially available kit, Technothrombin (Technoclone, Vienna, Austria). Factor V (FV) was identified by western blot analysis. DNA libraries were captured using ROCHE NimbleGen SeqCap ThromboGenomics capture baits (Roche NimbleGen, Inc, Madison, WI, USA) and sequenced using an Illumina Hiseq 4000 sequencer (Illumina, San Diego, CA, USA).

The scientists reported that TFPIα levels were higher in patients with bleeding compared with healthy controls (median 8.2 versus 7.8). A higher proportion of patients had free TFPIα levels more than or equal to the 95th percentile compared with healthy controls (odds ratio [OR], 2.82). This was pronounced in the subgroup of patients in whom no bleeding disorder could be identified (bleeding of unknown cause [BUC; n = 420]; OR 3.03) and in platelet function defects (PFDs) (n = 121; OR 3.47). An increase in free TFPIα was associated with a mild delay in thrombin generation (prolonged lag time and time to peak), but not with alterations in routinely used global clotting tests.

The authors concluded that free TFPIα is increased in patients with mild to moderate bleeding tendency and was associated with delayed thrombin generation. This could be an underlying cause or a contributor for bleeding, especially in patients with BUC and PFDs. they could neither identify new or known genetic variations in the F5 gene that are associated with neither free TFPIα levels, nor an influence of the single-nucleotide variant rs10800453 on free TFPIα levels in their patient cohort. An imbalance of natural coagulation inhibitors such as TFPIα could be an underlying cause or contributor for unexplained bleeding, which is most probably multifactorial in a majority of patients. The study was published on January 19, 2021 in the journal Blood Advances.

Related Links:
Medical University Vienna
Roche NimbleGen

Gold Supplier
SARS-CoV-2, Flu A/B, and RSV Test
Silver Supplier
Disposable Viral Preservation Tube
Disposable Viral Preservation Tube
Lateral Flow Test Reader
Direct Load Capture Cap Collection Kit
Direct Load Capture Cap Collection Kit

Print article
BIOHIT  Healthcare OY
Mayo Medical Laboratories


Molecular Diagnostics

view channel
Image: Photograph of the novel capsule-based smell test (Photo courtesy of Queen Mary University of London)

A Novel Capsule-Based Smell Test for Diagnosis of Neurological and Respiratory Diseases

To aid in diagnosing diseases where loss of the sense of smell is a symptom, such as in chronic neurological conditions like Parkinson's and Alzheimer's diseases and in acute respiratory infections such... Read more


view channel
Image: The Hamamatsu Photonics Nanozoomer 1 Digital Slide Scanner (Photo courtesy of University of Adelaide)

Genetic Background and Clinicopathologic Features Established for Adult-Onset Nephronophthisis

Nephronophthisis (NPH) is a genetic disorder of the kidneys which mainly affects children. It is classified as a medullary cystic kidney disease. The disorder is inherited in an autosomal recessive fashion... Read more


view channel
Image: DxA 5000 Fit (Photo courtesy of Beckman Coulter)

Beckman Coulter Becomes First Diagnostics Company to Offer Workflow Automation Specifically for Mid-Volume Laboratories

Beckman Coulter (Brea, CA, USA) has announced the global launch of the DxA 5000 Fit, a workflow-automation solution designed to fit into medium-sized labs that run fewer than 5,000 tests a day.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.